Clinical Trial Detail

NCT ID NCT03090165
Title Ribociclib and Bicalutamide in AR+ TNBC
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Ruth O'Regan, M.D.
Indications

triple-receptor negative breast cancer

Therapies

Bicalutamide + Ribociclib

Age Groups: adult senior

No variant requirements are available.